Refractory Burkitt Lymphoma

12 clinical trials · Condition

Record	Firm	Date
Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NCT04285268)	Rutgers, The State University of New Jersey	2020-05-06
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas (NCT03038672)	National Cancer Institute (NCI)	2018-12-21
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia (NCT03136146)	M.D. Anderson Cancer Center	2017-08-09
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NCT02992522)	Beth Christian	2017-02-21
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NCT02950220)	Kami Maddocks	2017-01-12
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma (NCT02568553)	National Cancer Institute (NCI)	2016-11-15
Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia (NCT02199184)	M.D. Anderson Cancer Center	2015-01-14
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas (NCT01897012)	National Cancer Institute (NCI)	2013-07-17
High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma (NCT01434472)	Fred Hutchinson Cancer Center	2011-11-16
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia (NCT01371630)	M.D. Anderson Cancer Center	2011-08-26

Track Refractory Burkitt Lymphoma automatically

Every clearance here is in the API, with alerts when new ones post.